Bridging the Gap: How SR&ED Financing can accelerate your R&D

On this page

Administrative processing delays are the primary reason R&D companies face cash flow gaps between spending and receiving their refunds. While the Canada Revenue Agency (CRA) aims to process accepted Scientific Research & Experimental Development (SR&ED) claims within 60 days, refundable claims selected for review have a service standard of 180 days .

In practice, this timeline often stretches to 4–8 months when reviews occur, creating a significant cash flow trough. For many founders we work with, the "60-day" target rarely aligns with operational realities. If a claim is reviewed, the dialogue with the CRA begins, creating a disconnect between when you incur expenses (payroll, materials) and when you recoup capital. For a scaling SME, this gap is hazardous; you have spent money to innovate, but reimbursement is locked in administrative limbo.

Operational impact on innovation

Often these delays force founders into reactive financing decisions. We frequently see companies planning product launches based on expected refunds, only to scramble for emergency capital when delays occur. This can lead to unfavourable terms, such as high-interest short-term loans or down-round equity raises. The operational momentum built during the R&D phase can grind to a halt while waiting for government processing. Treat the refund timeline as a variable rather than a guarantee to maintain momentum. The most successful CFOs we advise model the refund as a lagging indicator of cash flow rather than "certain cash." By acknowledging the volatility of processing times, you can build a capital strategy that insulates operations from bureaucratic delays. This involves setting up financing vehicles before a cash crunch occurs.

What is SR&ED Tax Credit Financing?

SR&ED financing transforms a retrospective tax refund into immediate working capital by securing a loan against your accrued tax credits. This allows companies to access capital quarterly or annually without waiting for the CRA's final assessment. Often referred to as an SR&ED bridge loan, this instrument provides liquidity based on the value of the government receivable you are generating through your R&D work.

The mechanics of the advance

Lenders typically advance a Loan-to-Value (LTV) between 70% and 80% of the accrued credit amount. This is a specialized form of asset-backed lending where the "asset" is the recoverability of your tax credit claim. If you have accrued $100,000 in SR&ED credits, a lender may advance you roughly $75,000 immediately. The remaining portion serves as a buffer for the lender in case the CRA reduces the claim. Once the CRA pays out the full refund, the loan principal and interest are repaid, and the remaining balance is released to you.

Quarterly cash advances vs. annual lump sums

Quarterly advances provide immediate liquidity by funding work as it happens, whereas annual lump sums force you to wait until after filing to access capital.

  • Annual: Funding is provided after the fiscal year ends and the claim is filed. This helps bridge the gap between filing and assessment but leaves you funding R&D out of pocket for the entire year.
  • Quarterly: Many providers offer R&D refund advance options on an accrual basis, advancing funds quarterly based on work completed.

With quarterly financing, your SR&ED refund functions as a steady revenue stream rather than a yearly bonus. As you run payroll in Q1, you can access the tax credits associated with that spend at the start of Q2. This dramatically reduces the working capital requirement needed to sustain aggressive R&D cycles.

Distinction from government programs

This is commercial debt, meaning it does not grind down your investment tax credit (ITC) base in the same way government funding might. SR&ED financing is a private transaction between your company and a lender. Unlike receiving a grant, which usually reduces your pool of eligible SR&ED expenditures, a properly structured commercial loan leaves your claim value intact. You pay interest to the lender, but you preserve the full principal value of your tax credit.

The cost of capital vs. the cost of dilution

The choice between financing and equity comes down to the difference between temporary interest costs and permanent ownership loss. When evaluating the cost of a bridge loan (interest + fees), compare it against the cost of selling equity at a lower valuation to cover the same operational gap.

Equity preservation is paramount

Paying 1–2% per month in interest is often cheaper than permanently selling a percentage of your company to survive a cash crunch. Founders often suffer from "sticker shock" when looking at the Annual Percentage Rate (APR), often 12–24%, of specialized debt. However, if you raise equity capital to cover a payroll gap, that equity is gone forever. As your company grows, that slice could be worth 10x or 20x its original value. In contrast, the interest paid on an SR&ED loan is a finite, tax-deductible business expense.

Non-dilutive venture debt benefits

SR&ED financing extends your runway to your next milestone, potentially increasing your valuation for the next raise. By using debt to bridge the gap, you avoid raising capital from a position of weakness. You can continue executing on your product roadmap, hitting key technical milestones, and acquiring users. When you eventually go to market for your Series A or B, you do so with better metrics. The cost of the financing is effectively an investment in a higher valuation.

Cashflow-first approach

We generally recommend optimizing for speed and certainty of capital over the absolute lowest interest rate when runway is tight. In a high-stakes R&D environment, liquidity is oxygen. Waiting months to secure a bank loan at a marginally lower rate is a strategic failure if it forces you to pause development. The opportunity cost of stalled innovation usually far outweighs the difference in interest points.

Next step:  Book Time with us To Consider your Options 

Banks vs. Specialized Lenders

Selecting the right lender requires balancing the lower cost of traditional banks against the speed and flexibility of specialized fintech providers. While traditional banks offer lower rates, specialized lenders provide the speed and flexibility required by high-growth R&D firms.

Traditional banks

For mature companies with established banking relationships, Tier 1 banks can be a viable option.

  • Pros: Lower interest rates are the main attraction.
  • Cons: Stringent eligibility criteria (profitability requirements), slower approval processes, and typically require a filed claim rather than offering quarterly advances.

Specialized SR&ED Lenders

Specialized fintech lenders offer faster deployment and higher LTV ratios by underwriting the tax credit asset rather than the company balance sheet. Zero to One works with a number of Partners that offer SR&ED financing, we're happy to connect you with them as part of our services to our clients.

  • Pros: Funding in days or weeks, higher LTV ratios (up to 80%), and willingness to lend against accrued credits before filing.
  • Trade-offs: While these providers offer speed, fees are generally higher than bank rates.

Selection criteria

Evaluate providers based on their understanding of the SR&ED program, transparency of fees, and flexibility regarding covenants. Look for hidden fees such as "setup fees" or "due diligence fees" that inflate the effective cost. Furthermore, consider if the lender requires a General Security Agreement (GSA) over all assets or just the receivable. A flexible lender will work with your broader capital stack, not restrict it.

Navigating Compliance

Compliance hinges on clearly distinguishing commercial "bona fide" loans from "government assistance" under the Income Tax Act. Correctly structured financing preserves the integrity of your tax credit claim, while poor structure risks reducing it. We anchor our advice in the Income Tax Act and under the Act, "government assistance" received in respect of SR&ED expenditures must be deducted from the pool of eligible expenditures, reducing your refund. However, commercial loans are not considered government assistance provided they are genuine commercial arrangements where the borrower has an unconditional obligation to repay. If a loan is forgivable or has terms that are exceptionally favourable due to government backing, the CRA might scrutinize it closer. The distinction is usually clear with private lenders, but founders must remain vigilant. The loan agreement should clearly outline standard commercial terms, interest repayment schedules, and recourse.

How to maximize LTV

Maintaining proactive, contemporaneous documentation is the single most effective way to secure higher loan-to-value (LTV) ratios and faster approvals. Lenders offer better terms, such as higher LTV and lower fees, when they trust the defensibility of the SR&ED claim. Further, a seamless handoff between your SR&ED preparer and your lender reduces diligence time. When you work with an integrated strategic partner, the technical narrative and financial data are already organized in a format that lenders trust. Lenders are essentially underwriting the risk that the CRA will deny your claim. If your consultant has a reputation for high success rates, the lender perceives lower risk. This translates directly to money in your pocket: lenders are more willing to advance higher LTV if they are confident the claim will hold up to CRA scrutiny.

Lender-ready checklist

A complete lender-ready checklist includes contemporaneous technical notes, accurate payroll journals, and a clean filing history.

  • Technical notes: Dated records of your experiments, hypotheses, and conclusions.
  • Payroll journals: Clear breakdown of time spent by each employee on eligible projects, tracked monthly.
  • Filing history: Evidence of past claims helps establish a track record of compliance.

The value of consistency

Moving from reactive year-end filing to quarterly tracking allows for quarterly advances. "Messy" claims often result in lower LTVs or rejection, while strong documentation facilitates faster approvals. If a lender has to spend weeks untangling your payroll data, your funding will be delayed. Conversely, a company that utilizes a proactive documentation system can often get approved for accrual financing in days.

Next step:  Book a meeting to explore this approach 

Strategic stacking

Combining SR&ED financing with grants creates a robust capital stack that stabilizes cash flow better than any single program alone. We view non-dilutive funding through four main pillars: Tax Credits, Grants, Wage Subsidies, and Government Loans. By using  our non-dilutive consulting and support services  to integrate annual SR&ED claims alongside other government programs and grants, you also avoid reliance on a single source of funds. In general, we suggest that companies use SR&ED financing to address immediate working capital needs, providing the stability required to apply for longer-term grant projects without desperation. Grants are excellent for forward-looking projects, but they often have long lead times. SR&ED financing can act as the high-velocity capital that keeps the lights on while you wait for larger, slower grant disbursements.

Avoiding silos

Working with a single strategic partner who oversees the entire non-dilutive stack prevents conflicting claims. A common error is inadvertently claiming the same expense twice, once for SR&ED and again within a grant applicatio This is "double-dipping" and is strictly prohibited. An integrated approach ensures that every dollar of spend is allocated to the optimal program, maximizing your total funding while remaining 100% compliant.

Next step:  Book a Call with our Team

FAQs

Q: Does SR&ED financing reduce the amount of my final refund?A: No, it is a commercial loan. However, interest and fees are costs you pay. The principal is repaid from the refund, but the claim value itself remains intact (unlike government funding).

Q: Can I get financing if I haven't filed my tax return yet?A: Yes, many lenders offer "accrual" financing, advancing funds quarterly based on work completed, even before the fiscal year ends.

Q: What happens if the CRA reviews or reduces my claim?A: You are responsible for the shortfall. If the CRA pays less than the loan amount, you must pay the difference to the lender. This is why defensible documentation is critical.

Q: How long does it take to get funded?A: Once your technical and financial diligence is complete, funding can often be deployed in 1–2 weeks

Related posts

Your next funding opportunity is closing soon

Let’s connect before it's too late.